The research company Pharmalundensis reports, as planned, no revenue during the fourth quarter. The operating loss increased.Operating result was SEK -1.9 million (-1.0). Result before and after tax was SEK -1.9 million (-1.1). Earnings per share amounted to SEK -0.03 (-0.02). Cash flow from operating activities amounted to SEK -1.5 million (-1.4). Cash and cash equivalents amounted to SEK 1.2 million (1.3). The company is carrying out a share issue of SEK 20 million in February this year.No dividend is proposed."I assess that 2026 could be a decisive year when Pharmalundensis gradually transitions tobecome a profitable company that can finance the company's clinical studies itself!", says Staffan Skogvall, the company's CEO.Pharmalundensis, SEK millionQ4-2025Q4-2024Net sales00.0Operating result-1.9-1.0Result before tax-1.9-1.1Net result-1.9-1.1Earnings per share, SEK-0.03-0.02Cash flow from operating activities-1.5-1.4Cash and cash equivalents1.21.3